Literature DB >> 12442683

Renaissance of amantadine in the treatment of Parkinson's disease.

Pierre J Blanchet1, Leo Verhagen Metman, Thomas N Chase.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12442683

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


× No keyword cloud information.
  14 in total

1.  Solid-state NMR and MD simulations of the antiviral drug amantadine solubilized in DMPC bilayers.

Authors:  Conggang Li; Myunggi Yi; Jun Hu; Huan-Xiang Zhou; Timothy A Cross
Journal:  Biophys J       Date:  2007-09-21       Impact factor: 4.033

2.  Distribution and dynamics of adamantanes in a lipid bilayer.

Authors:  Chee Foong Chew; Andrew Guy; Philip C Biggin
Journal:  Biophys J       Date:  2008-10-03       Impact factor: 4.033

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 4.  Novel approaches to the treatment of cocaine addiction.

Authors:  Mehmet Sofuoglu; Thomas R Kosten
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Amantadine inhibits NMDA receptors by accelerating channel closure during channel block.

Authors:  Thomas A Blanpied; Richard J Clarke; Jon W Johnson
Journal:  J Neurosci       Date:  2005-03-30       Impact factor: 6.167

6.  Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.

Authors:  Weixing Shen; Wenjie Ren; Shenyu Zhai; Ben Yang; Carlos G Vanoye; Ananya Mitra; Alfred L George; D James Surmeier
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

7.  Parkinson's disease: genetics and beyond.

Authors:  N N Inamdar; D K Arulmozhi; A Tandon; S L Bodhankar
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

8.  Altered neuronal activity relationships between the pedunculopontine nucleus and motor cortex in a rodent model of Parkinson's disease.

Authors:  Bhooma R Aravamuthan; Debra A Bergstrom; Robin A French; Joseph J Taylor; Louise C Parr-Brownlie; Judith R Walters
Journal:  Exp Neurol       Date:  2008-06-09       Impact factor: 5.330

9.  Specific features of sensorimotor cerebral cortex activity modulation by dopamine releaser amantadine.

Authors:  Viktor M Storozhuk; Larissa E Zinyuk
Journal:  Exp Brain Res       Date:  2007-05-24       Impact factor: 1.972

Review 10.  Treatment strategies for Parkinson's disease.

Authors:  Hong Yuan; Zhen-Wen Zhang; Li-Wu Liang; Quan Shen; Xiang-Dang Wang; Su-Mei Ren; Hong-Jie Ma; Shu-Jun Jiao; Ping Liu
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.